Reversible cardiomyopathy due to secondary hemochromatosis with multitransfusions for severe aplastic anemia after successful non-myeloablative stem cell transplantation

International Journal of Cardiology

Volumn 127, Issue 3, 2008, Pages 400-401

  Nishio, M ^a   Endo, T ^a   Nakao, S ^b   Sato, N ^c   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Graduate School of Medicine   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aplastic anemia; Cardiomyopathy; Hemochromatosis; Stem cell transplantation

Indexed keywords

FUROSEMIDE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOMEGALY; CARDIOMYOPATHY; CASE REPORT; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEMOCHROMATOSIS; HOSPITAL ADMISSION; HUMAN; IRON OVERLOAD; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; ANEMIA, APLASTIC; BLOOD TRANSFUSION; CARDIOMYOPATHIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; STEM CELL TRANSPLANTATION;

EID: 45849127663     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.04.066     Document Type: Article

References (9)

1. Blank R., Wolber T., Maeder M., and Rickli H. Reversible cardiomyopathy in a patient with juvenile hemochromatosis. Int J Cardiol 111 (2006) 161-162
2. Nishio M., Nakao S., Endo T., et al. Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure. Bone Marrow Transplant 28 (2001) 783-785
3. Endo T., Nakao S., Koizumi K., et al. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient. Ann Hematol 83 (2004) 114-116
4. Hoyes K.P., Jones H.M., Abeysinghe R.D., Hider R.C., and Porter J.B. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis. Exp Hematol 21 (1993) 86-92
5. Lee P., Mohammed N., Marshall L., et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 21 (1993) 640-644
6. Summers M.R., Jacobs A., Tudway D., Perera P., and Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42 (1979) 547-555
7. McAllen P.M., Coghill N.F., and Lubran M. The treatment of haemochromatosis; with particular reference to the removal of iron from the body by repeated venesection. Q J Med 26 (1957) 251-276
8. Fabio G., Minonzio F., Delbini P., Bianchi A., and Cappellini M.D. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by severe type of juvenile hemochromatosis (JH). Blood (2006)
9. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., and Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313 (1985) 1256-1262